drugset / Trial / NCT05749289
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
Phase 2/3
Recruiting
400 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelDiagnostic
Summary
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
Timeline
- Start
- 2022-12-20
- Primary completion
- 2028-12-20
- Completion
- 2029-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Al18F-octreotide | Diagnostic / imaging agent | — | — |
Indications
No indication recorded.